Suzetrigine for Opioid-Free Recovery After C-Section

(SPARE Trial)

This trial explores whether suzetrigine, a new potential drug, can help women remain opioid-free for 72 hours after a C-section. Participants will receive either suzetrigine or a placebo, alongside standard pain treatments like acetaminophen and anti-inflammatory drugs. The study aims to determine if suzetrigine can reduce the need for opioids post-surgery. Women undergoing a C-section with planned spinal or epidural anesthesia, who agree not to provide breast milk during the study period, might be suitable candidates. This trial offers an opportunity to explore a new method of managing pain after delivery without relying on opioids. As a Phase 4 trial, suzetrigine has already received FDA approval and proven effective, and this research seeks to understand its benefits for more patients.

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are using medications that significantly alter suzetrigine metabolism, like ketoconazole or St. John's wort.

Research has shown that suzetrigine is generally safe and well-tolerated. One study combined safety data from over 2,000 people, revealing that the most common side effects were mild, such as itching (experienced by 2.1% of participants) and muscle pain. No serious side effects were reported.

Suzetrigine is a non-opioid pain medicine that blocks certain pain signals. The FDA has already approved it for other types of short-term pain, indicating it has passed strict safety checks for those uses.

Researchers are excited about suzetrigine because it offers a potential path to opioid-free recovery after a C-section. Unlike standard treatments that often rely on opioids for managing postoperative pain, suzetrigine is an oral medication designed to be part of a multimodal pain management approach, reducing the need for opioids and their associated risks. This new option, combined with acetaminophen and nonsteroidal anti-inflammatory drugs, aims to effectively manage pain while minimizing opioid exposure, which is a significant advancement in post-surgical care.

Research has shown that suzetrigine effectively manages pain after surgery. In earlier studies, 90.9% of patients undergoing reconstructive and cosmetic surgery recovered without needing opioids. This trial will evaluate suzetrigine as a potential option for women to avoid opioids for pain relief after a C-section. Participants will receive either suzetrigine or a placebo, alongside standardized multimodal postoperative analgesia. As a non-opioid pain reliever, suzetrigine can ease pain without the side effects often linked to opioids. It has a good safety record, with fewer side effects like nausea and dizziness compared to typical pain medications. Overall, suzetrigine appears to be a promising option for managing pain.⁶⁷⁸⁹¹⁰